Nicoler Hadas News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nicoler hadas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nicoler Hadas Today - Breaking & Trending Today
Akebia Therapeutics (NASDAQ:AKBA) Given "Neutral" Rating at HC Wainwright modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) will be releasing its earnings data on Wednesday, August 2nd. Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The business had revenue […] ....
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) saw a large growth in short interest in June. As of June 30th, there was short interest totalling 4,840,000 shares, a growth of 11.3% from the June 15th total of 4,350,000 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is currently 2.7 […] ....
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.95 and traded as high as $1.28. Akebia Therapeutics shares last traded at $1.23, with a volume of 1,657,800 shares. Analyst Ratings Changes AKBA has been the subject […] ....
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Wednesday, The Fly reports. Other analysts also recently issued reports about the company. StockNews.com downgraded Akebia Therapeutics from a “buy” rating to […] ....